Neal Beswick

Neal joined Transplant Genomics in August 2020 and is the VP of commercial operations. Neal has worked in the commercial transplant field for over 15 years focused on advanced preservation systems for all solid organs and molecular biomarkers for the kidney and liver during his 4 year tenure at Transplant Genomics. The transplant field and more specifically the pursuit of improving patient outcomes post-transplant is a passion for Neal where knowledge and imagination can fuel much needed innovation in guiding monitoring and therapy titration.

Vice President of Commercialization

James Fleming, PharmD, FCCP, FAST

Dr. Fleming joined Transplant Genomics in November 2021 and is the Director of Medical Affairs and Clinical Trials. Dr. Fleming is transplant pharmacist with 11 years of clinical and academic experience
in both abdominal and cardiothoracic transplant and 5 years of biotechnology industry experience in medical affairs and clinical trials. He has authored over 100 scientific abstracts and over 50 peer-reviewed manuscripts that have appeared in numerous journals, including the American Journal of Transplantation. He has served as affiliate faculty for the Colleges of Pharmacy and Medicine at the Medical University of South Carolina.
Dr. Fleming earned his PharmD at the University of Iowa College of Pharmacy and completed his residency and solid organ transplant specialty residencies at UMass
Memorial Medical Center and the Medical University of South Carolina, respectively. He is currently completing his MPH at the Medical University of South Carolina College of Medicine, pending completion in December 2024.

Director of Medical Affairs and Clinical Trials

Jon Friedman, MD, FAST

Jon Friedman, MD, FAST, joined Transplant Genomics as Chief Medical Officer in February 2022 after 22 years with Optum/United Health Group. Prior to joining TGI, Dr. Friedman was the Chief Medical Officer of Optum’s Medical Benefit Management division for 10 years where he had direct oversight of the solid organ and bone marrow transplants, as well as chronic and end-stage renal disease. Dr. Friedman is a Fellow of the American Society of Transplantation and received an AST Distinguished Service Award for his efforts in breaking down financial barriers in support of living kidney donors. He is a co-founder of United Health Group’s HERO (Helping Employees Receive Organs) Program. Dr. Friedman received his BA in Biochemistry from the University of Pennsylvania, his MD from Washington University in St. Louis, and his Fellowship in Geriatric Medicine from UCLA.

Chief Medical Officer

Steve Kleiboeker, DVM, PhD

Steve Kleiboeker, DVM, PhD, Vice President of Research and Development, is responsible for the scientific direction and oversight of the Company’s research and development programs. Dr. Kleiboeker’s research focuses on diagnostic virology, immunology and infectious diseases as well as transplant monitoring. He is board certified as a high-complexity laboratory director, technical supervisor and clinical consultant by the American Board of Bioanalysis. Dr. Kleiboeker received his PhD and DVM from the University of Missouri.

Vice President of Research and Development & Lab Director

Leadership